WD Rutherford LLC reduced its stake in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 80.7% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,354 shares of the medical research company's stock after selling 5,657 shares during the period. WD Rutherford LLC's holdings in Thermo Fisher Scientific were worth $549,000 at the end of the most recent reporting period.
Several other hedge funds have also recently modified their holdings of the business. James Hambro & Partners LLP lifted its position in shares of Thermo Fisher Scientific by 9.8% in the 2nd quarter. James Hambro & Partners LLP now owns 257,327 shares of the medical research company's stock worth $104,296,000 after purchasing an additional 22,904 shares during the period. Avior Wealth Management LLC lifted its position in shares of Thermo Fisher Scientific by 24.5% in the 2nd quarter. Avior Wealth Management LLC now owns 4,096 shares of the medical research company's stock worth $1,661,000 after purchasing an additional 806 shares during the period. Charles Schwab Trust Co lifted its position in shares of Thermo Fisher Scientific by 50.2% in the 2nd quarter. Charles Schwab Trust Co now owns 673 shares of the medical research company's stock worth $273,000 after purchasing an additional 225 shares during the period. Spirepoint Private Client LLC lifted its position in shares of Thermo Fisher Scientific by 2.4% in the 2nd quarter. Spirepoint Private Client LLC now owns 11,483 shares of the medical research company's stock worth $4,656,000 after purchasing an additional 272 shares during the period. Finally, Processus Wealth & Capital Management LLC lifted its position in shares of Thermo Fisher Scientific by 2.9% in the 2nd quarter. Processus Wealth & Capital Management LLC now owns 6,287 shares of the medical research company's stock worth $2,549,000 after purchasing an additional 180 shares during the period. Hedge funds and other institutional investors own 89.23% of the company's stock.
Insider Activity
In other news, EVP Gianluca Pettiti sold 400 shares of Thermo Fisher Scientific stock in a transaction dated Friday, July 25th. The shares were sold at an average price of $479.98, for a total value of $191,992.00. Following the sale, the executive vice president owned 22,367 shares in the company, valued at $10,735,712.66. This trade represents a 1.76% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Marc N. Casper sold 400 shares of Thermo Fisher Scientific stock in a transaction dated Friday, September 5th. The shares were sold at an average price of $500.50, for a total transaction of $200,200.00. Following the completion of the sale, the chief executive officer owned 113,762 shares in the company, valued at approximately $56,937,881. This trade represents a 0.35% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 30,066 shares of company stock worth $14,182,963 over the last 90 days. 0.33% of the stock is currently owned by company insiders.
Wall Street Analyst Weigh In
A number of research firms recently commented on TMO. William Blair began coverage on shares of Thermo Fisher Scientific in a research report on Monday, August 18th. They set an "outperform" rating for the company. Barclays raised shares of Thermo Fisher Scientific from an "equal weight" rating to an "overweight" rating and raised their price target for the stock from $490.00 to $550.00 in a report on Thursday, September 11th. Raymond James Financial reaffirmed an "outperform" rating and issued a $535.00 price target (up previously from $525.00) on shares of Thermo Fisher Scientific in a report on Thursday, July 24th. Royal Bank Of Canada set a $561.00 price target on shares of Thermo Fisher Scientific and gave the stock an "outperform" rating in a report on Tuesday, September 2nd. Finally, Hsbc Global Res cut shares of Thermo Fisher Scientific from a "strong-buy" rating to a "hold" rating in a report on Thursday, July 24th. Sixteen analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company's stock. According to data from MarketBeat.com, Thermo Fisher Scientific has a consensus rating of "Moderate Buy" and an average target price of $588.35.
Read Our Latest Research Report on Thermo Fisher Scientific
Thermo Fisher Scientific Stock Up 1.1%
TMO stock opened at $464.18 on Friday. The firm has a market cap of $175.28 billion, a PE ratio of 26.85, a P/E/G ratio of 2.52 and a beta of 0.75. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.50 and a current ratio of 1.93. The firm's fifty day moving average is $476.70 and its 200 day moving average is $447.57. Thermo Fisher Scientific Inc. has a one year low of $385.46 and a one year high of $623.77.
Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last released its quarterly earnings results on Wednesday, July 23rd. The medical research company reported $5.36 EPS for the quarter, beating the consensus estimate of $5.22 by $0.14. The company had revenue of $10.86 billion for the quarter, compared to analyst estimates of $10.68 billion. Thermo Fisher Scientific had a net margin of 15.24% and a return on equity of 16.82%. The firm's revenue was up 2.9% on a year-over-year basis. During the same quarter last year, the business earned $5.37 earnings per share. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. On average, research analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.
Thermo Fisher Scientific Announces Dividend
The business also recently announced a quarterly dividend, which will be paid on Wednesday, October 15th. Stockholders of record on Monday, September 15th will be given a $0.43 dividend. The ex-dividend date is Monday, September 15th. This represents a $1.72 annualized dividend and a dividend yield of 0.4%. Thermo Fisher Scientific's dividend payout ratio (DPR) is 9.95%.
Thermo Fisher Scientific Company Profile
(
Free Report)
Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.
Further Reading
Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Thermo Fisher Scientific, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Thermo Fisher Scientific wasn't on the list.
While Thermo Fisher Scientific currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
